SCHEMBL4236265

SCHEMBL4236265

COc1nc(NCCNC(C)C)nc(OC)c1NC(=O)c1csc(Oc2cc(OC(C)C)ccc2C)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNRHR P30968 2/20 0.35
LMNA P02545 5/20 0.34
GAA P10253 1/20 0.34
ALOX12 P18054 1/20 0.34
MAPT P10636 4/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
CACNA1F O60840 1/20 0.33
CHRM4 P08173 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CHRM1 P11229 1/20 0.33
CYP2C9 P11712 1/20 0.33
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33
SLC6A2 P23975 1/20 0.33
HRH2 P25021 1/20 0.33
TACR1 P25103 1/20 0.33
PTAFR P25105 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
AGTR1 P30556 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233362 0.95 GNRHR (0.36) GNRHRLMNAGAAALOX12MAPT
SCHEMBL4231750 0.92 GNRHR (0.34) GNRHRLMNAGAAALOX12MAPT
SCHEMBL4236000 0.92 ACACB (0.35) GNRHRLMNAGAAALOX12MAPT
SCHEMBL4233424 0.91 ACACB (0.34) GNRHRLMNAGAAALOX12MAPT
SCHEMBL4231861 0.90 GNRHR (0.36) GNRHRLMNAGAAMAPTCACNA1F
SCHEMBL4237726 0.90 GNRHR (0.36) GNRHRLMNAMAPTSMN1; SMN2CACNA1F
SCHEMBL4228389 0.88 GNRHR (0.35) GNRHRMAPTCACNA1FCHRM4ADORA3
SCHEMBL14621838 0.88 MAPT (0.32) GNRHRMAPTSMN1; SMN2CACNA1FCHRM4
SCHEMBL4237638 0.88 GNRHR (0.34) GNRHRCACNA1FCHRM4ADORA3CHRM1
SCHEMBL4235884 0.87 LMNA (0.32) GNRHRLMNAGAAALOX12MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209522-A1 Heterocyclic Non-Peptide GNRH Antagonists TAKEDA CAMBRIDGE LIMITED (GB) 2009-08-20 US claimed
US-20090209522-A1 Heterocyclic Non-Peptide GNRH Antagonists TAKEDA CAMBRIDGE LIMITED (GB) 2009-08-20 US disclosed
US-20090209522-A1 Heterocyclic Non-Peptide GNRH Antagonists TAKEDA CAMBRIDGE LIMITED (GB) 2009-08-20 US disclosed
EP-1896465-A1 HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS Takeda Cambridge Limited (GB) 2008-03-12 EP disclosed
WO-2007000582-A1 HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS TAKEDA CAMBRIDGE LIMITED (GB) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209522-A1 Heterocyclic Non-Peptide GNRH Antagonists GNRHR, GHRHR, FSHR GNRHR 1/4885LMNA 2647/4885GAA 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.